


USSN 10/643,411

CT-2645-DIV1

Amendments to the claims

1. (currently amended) A compound of Formula I, and pharmaceutically acceptable salts thereof,



Formula I

wherein:

R_1 is $-(CR^aR^b)_n-X$;

R^a, R^b are each independently selected from the group consisting of H, C_{1-6} alkyl; each of said C_{1-6} alkyl being optionally substituted with one to six same or different halogen;

X is H or C_{1-6} alkyl; said C_{1-6} alkyl being optionally substituted with a member selected from the group consisting of (1) one to six same or different halogen or hydroxy, (2) ~~heterocaryl~~ pyrrolidinyl, methylpyrrolidinyl, piperidinyl, 1,2,4-oxadiazolyl, or tetrazolyl, and (3) ~~non-aromatic heterocyclic ring and (4) a member selected from Group A;~~

n is 1-6;

Group A is a member selected from the group consisting of halogen, CN, OR^x , $N^+R^cR^dR^e[T]$, NR^cR^d , COR^e , CO_2R^x , $CONR^xR^y$ and $S(O)_mR^e$;

R^x and R^y are independently H or C_{1-6} alkyl;

R^c, R^d and R^e are independently C_{1-6} alkyl;

m is 0-2

T is halogen, $CF_3SO_3^-$ or $CH_3SO_3^-$;


R_2 and R_5 are independently halogen or H;

R_3 and R_4 are each independently selected from the group consisting of H, halogen and C_{1-6} alkyl; said C_{1-6} alkyl can be optionally substituted with one to six same or different halogen;

USSN 10/643,411

CT-2645-DIV1

Q is a member selected from the group consisting of



USSN 10/643,411

CT-2645-DIV1

F_1 is CH or N;

R_6 is selected from the group consisting of H, halogen, NR^fR^g , SR^h and a five-membered heteroaryl containing one to two of the same or different heteroatoms selected from the group consisting of O, S and N thiazolyl;

R^f and R^g are independently H, C_{1-6} alkyl or C_{1-8} alkyl; said C_{1-6} alkyl optionally substituted with OR^h or CO_2R^h ;

R^h and R^i are independently H or C_{1-8} alkyl;

R^j is C_{1-6} alkyl optionally substituted with CO_2R^h ;

R_7 is H, or CO_2R^h ;

R_8 is H, COR^h , CO_2R^h or C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with OR^h ;

R_9 is H, halogen, heteroaryl pyridinyl, phenyl, phenyl substituted with a halogen group, phenyl substituted with a methanesulfonyl group, COR^h , CO_2R^h , C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-4} alkynyl; said C_{2-4} alkynyl optionally substituted with C_{1-6} cycloalkyl;

R_{10} and R_{11} are independently H, NO_2 or NR^hR^i

R_{12} is H, CO_2R^h or C_{1-2} alkyl; said C_{1-2} alkyl optionally substituted with phenyl;

R_{13} and R_{14} are independently selected from the group consisting of H, OR^h , $CONR^fR^g$, NR^fR^m and pyrrolidine; wherein said pyrrolidine is attached at the nitrogen atom;

R^j and R^k are independently H or C_{1-6} alkyl optionally substituted with phenyl;

R^l and R^m are independently C_{1-6} alkyl;

R_{15} and R_{16} are independently selected from the group consisting of H, OR^h , phenyl, pyridyl and C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with CO_2R^h ;

R_{17} and R_{18} are independently selected from the group consisting of halogen, NR^fR^m , SR^h and morpholine; wherein said morpholine is attached at the nitrogen atom;

USSN 10/643,411

CT-2645-DIV1

R_{19} is selected from the group consisting of H, phenyl, C_{2-6} alkenyl and C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with one to six same or different halogen, CO_2R^h , $CONR^hR^l$, pyridyl and one to three phenyl groups; wherein in the case of C_{1-6} alkyl substituted with one phenyl group, said phenyl group is optionally substituted with a member selected from the group consisting of halogen, $PO(OR^h)_2$, CO_2R^h , SO_2R^h and $CONR^hR^l$;

R^n is C_{1-6} alkyl;

R_{20} and R_{21} are independently H or halogen;

R_{22} is C_{1-6} alkyl;

R_{23} and R_{24} are independently H or C_{1-6} alkyl;

R_{25} is C_{1-6} cycloalkyl or C_{1-6} alkyl; said C_{1-6} alkyl group optionally substituted with a member selected from the group consisting of CO_2R^h , $PhCO_2R^h$ and one to six same or different halogens;

~~heteroaryl is a 5- or 6-membered aromatic ring containing at least one and up to four non-carbon atoms selected from the group consisting of O, N and S;~~

~~non-aromatic heterocyclic ring is a 3 to 7-membered non-aromatic ring containing at least one and up to four non-carbon atoms selected from the group consisting of O, N and S; and~~

p is 0-2.

2. (canceled)

3. (canceled)

4. (original) A compound of claim 1 wherein:

R^a and R^b are hydrogen.

5. (original) A compound of claim 1 wherein:

USSN 10/643,411

CT-2645-DIV1


R_1 is $-(CH_2)_n-X$ and n is 2-4.

6. (original) A compound in claim 1 wherein R_3 and R_4 are each independently selected from the group consisting of H, fluorine and C_{1-2} alkyl; said C_{1-2} alkyl being optionally substituted with one to three fluorine atoms.

7. (original) A compound in claim 1 wherein:

R_1 is 3-methyl-2-butyl or $-(CH_2)_n-X$; wherein n is 2-4;

X is a member selected from the group consisting of
 $-F$, $-CN$, $-SR^c$, $-SO_2R^c$, $-OR^x$, $-COR^c$, CO_2R^x , $CONR^xR^y$,
 $[NR^cR^dR^e][T]$.



R^c , R^d and R^e are independently C_{1-4} alkyl; and

R^x and R^y are independently H or C_{1-4} alkyl.

8. (original) A compound of claim 1 wherein:

R_2 and R_6 are independently H.

9. (original) A method for treating mammals infected with RSV, and in need thereof, which comprises administering to said mammal a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1-8.

USSN 10/643,411

CT-2645-DIV1

10. (original) A pharmaceutical composition which comprises a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1-8, and a pharmaceutically acceptable carrier.